--- title: "Annovis Bio | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286607190.md" datetime: "2026-05-15T20:06:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286607190.md) - [en](https://longbridge.com/en/news/286607190.md) - [zh-HK](https://longbridge.com/zh-HK/news/286607190.md) --- # Annovis Bio | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.63, missing the estimate of USD -0.395. EBIT: As of FY2026 Q1, the actual value is USD -18.15 M. ### Financial Overview #### Cash and Cash Equivalents Annovis Bio, Inc.’s cash and cash equivalents were $14,219,081 as of March 31, 2026, a decrease from $19,532,338 as of December 31, 2025. This figure does not include gross proceeds from a $10.0 million registered direct offering on April 10, 2026. #### Total Assets Total assets were $16,243,703 as of March 31, 2026, down from $21,081,625 as of December 31, 2025. #### Total Liabilities Total liabilities increased to $13,117,645 as of March 31, 2026, from $4,230,375 as of December 31, 2025. #### Total Stockholders’ Equity Total stockholders’ equity was $3,126,058 as of March 31, 2026, compared to $16,851,250 as of December 31, 2025. #### Research and Development Expenses Research and development expenses for the three months ended March 31, 2026, were $16,720,362, a significant increase from $5,011,517 for the same period in 2025. #### General and Administrative Expenses General and administrative expenses for the three months ended March 31, 2026, were $1,291,820, slightly up from $1,271,164 for the three months ended March 31, 2025. #### Operating Loss The operating loss for the three months ended March 31, 2026, was - $18,012,182, compared to - $6,282,681 for the same period in 2025. #### Interest Income Interest income for the three months ended March 31, 2026, was $137,800, down from $187,612 for the three months ended March 31, 2025. #### Change in Fair Value of Warrants The change in fair value of warrants resulted in an income of $268,000 for the three months ended March 31, 2026, compared to an income of $558,000 for the same period in 2025. #### Net Loss Annovis Bio, Inc. reported a net loss of - $17,606,382 for the three months ended March 31, 2026, compared to a net loss of - $5,537,069 for the three months ended March 31, 2025. #### Basic and Diluted Net Loss Per Common Share Basic and diluted net loss per common share was - $0.63 for the three months ended March 31, 2026, compared to - $0.32 for the three months ended March 31, 2025. #### Shares Outstanding Annovis Bio, Inc. had 28,537,302 shares of common stock outstanding as of March 31, 2026, compared to 27,199,139 shares outstanding as of December 31, 2025. ### Operational Highlights #### Alzheimer’s Disease (AD) – Pivotal Phase 3 Trial Enrollment for the Phase 3 AD trial reached 85% of patients, with new participant enrollment closing on May 15, 2026, after achieving a sufficient number of patients in screening. The Data and Safety Monitoring Board (DSMB) provided a positive recommendation on the drug’s safety at 6 months, allowing for the study’s continuation. #### Parkinson’s Disease (PD) – Open-Label Extension (OLE) Study Enrollment for the PD OLE study reached 40% of patients, incorporating a skin biomarker test and partnering with NeuroRPM for an AI-powered digital biomarker for continuous motor function assessment. #### Corporate Highlights Annovis Bio, Inc. published an article in _The Scientist_ tracing buntanetap’s history and announced a peer-reviewed publication of Phase 2⁄3 AD clinical trial results in _Nature NPJ Dementia_, demonstrating dose-dependent cognitive improvement and biomarker reductions. The company also presented clinical data at AD/PD2026 and Fierce Biotech Week 2026, and secured a U.S. patent for preventing and treating neurological injuries from brain infections using buntanetap. ### Outlook / Guidance Annovis Bio, Inc. expects to achieve full enrollment for the Phase 3 AD study in summer 2026, with symptomatic data readout anticipated approximately 6 months after the last patient is dosed and disease-modifying data readout 18 months after. The company anticipates completing enrollment for the PD OLE study in the fourth quarter of 2026. Based on Phase 3 AD study outcomes, Annovis Bio, Inc. plans to engage with the FDA for a regulatory New Drug Application (NDA) submission for buntanetap as a symptomatic treatment for AD in early 2027 and as a disease-modifying treatment in early 2028. ### Related Stocks - [ANVS.US](https://longbridge.com/en/quote/ANVS.US.md) ## Related News & Research - [Annovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period](https://longbridge.com/en/news/287724562.md) - [Factorial Files Super 8-K Containing Q1 2026 Financial Results | FAC Stock News](https://longbridge.com/en/news/289602927.md) - [Why Is Climb Bio Stock Gaining Friday?](https://longbridge.com/en/news/289612125.md) - [David E. Shaw Discloses Investment at Gossamer Bio with 9.5% Stake](https://longbridge.com/en/news/289530895.md) - [Summit Therapeutics withdraws proposed underwritten offering citing market conditions](https://longbridge.com/en/news/289460448.md)